The global Tourette's syndrome drugs market size will grow by USD 98.77 million during 2019-2023. This market report provides a detailed analysis of the market by product (antipsychotics and non-antipsychotics) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market's competitive landscape and offers information on several market vendors, including AstraZeneca Plc, Boehringer Ingelheim International GmbH, Eli Lilly and Co., H. Lundbeck AS, Johnson & Johnson Services Inc., Mylan NV, Otsuka Holdings Co. Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
Key Insights on Tourette's Syndrome Drugs Market - Global Forecast 2019-2023
Browse TOC and LoE with selected illustrations and example pages of Tourette's Syndrome DrugsMarket
The development of novel therapeutics has been identified as one of the critical Tourette's syndrome drugs market trends driving market growth. Several pharmaceutical companies and researchers are focusing on the development of novel drugs that correct the dopaminergic disturbances responsible for motor and vocal tics in Tourette's syndrome patients. For instance, ecopipam, a first-in-class drug developed by Emalex Biosciences, selectively blocks the actions of the neurotransmitter dopamine at the D1 receptor pediatric patients. Similarly, ABX-143, a first-in-class, small molecule monoacylglycerol lipase inhibitor is being developed by Abide Therapeutics Inc. (Abide Therapeutics). Also, Therapix Biosciences is evaluating the efficacy and safety of THX-110, a drug candidate platform for the treatment of symptoms related to Tourette's syndrome. The development of such novel therapeutics will fuel the growth of the Tourette's syndrome drugs market throughout the next five years.
According to the Tourette's syndrome drugs market forecast report, the morbid nature of the disease will also drive the growth of the market. Patients with Tourette's syndrome produce repetitive, involuntary movements and unwanted sound collectively termed as tics. Tourette's syndrome is also accompanied by various other conditions, such as attention deficit hyperactivity disorder, obsessive-compulsive disorder, depression, and sleeping disturbances. These conditions affect the quality of life of the patients and results in poor psychosocial functioning. Several non-antipsychotic and atypical antipsychotic drugs, such as quetiapine, olanzapine, risperidone, and aripiprazole are available at low cost that helps in suppressing tics in patients with Tourette's syndrome. The low cost of drugs and the morbid nature of syndrome will boost the adoption of Tourette's syndrome drugs and drive the growth of the market at a CAGR of almost 5% during the forecast period.
Top Companies in Tourette's Syndrome Drugs Market
The global market is fragmented. To help clients improve their market position, this report provides an analysis of the market's competitive landscape and offers information on the products offered by various companies. Moreover, this Tourette's syndrome drugs market analysis report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make most of the upcoming growth opportunities.
The report offers a detailed analysis of several leading Tourette's syndrome drugs manufacturers, including:
Boehringer Ingelheim International GmbH
Eli Lilly and Co.
H. Lundbeck AS
Johnson & Johnson Services Inc.
Otsuka Holdings Co. Ltd.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Tourette's Syndrome Drugs Market by Product
The antipsychotics segment will account for the highest Tourette's syndrome drugs market share. The strong therapeutic value of antipsychotics is one of the significant factors driving the growth of the Tourette's syndrome drugs market in this segment. This market research report provides an accurate prediction of the contribution of all the segments to the growth of the Tourette's syndrome drugs market size.
Tourette's Syndrome Drugs Market by Region
With a complete study of the growth opportunities for companies, it has been identified that North America will account for the highest share of the Tourette syndrome drugs market throughout the forecast period. Factors such as the development of novel drugs and strong prevalence of Tourette's syndrome are contributing to the Tourette's syndrome drugs market growth in this region.
Major Highlights of the Tourette's Syndrome Drugs Market - Global Forecast 2019-2023
CAGR of the market during the forecast period 2019-2023
Detailed information on factors that will accelerate the growth of the Tourette's syndrome drugs market during the next five years
Precise estimation of the global Tourette syndrome drugs market size and its contribution to the parent market
Accurate predictions on upcoming trends and changes in consumer behavior
The growth of the Tourette's syndrome drugs industry across Asia, Europe, North America, and ROW
A thorough analysis of the market's competitive landscape and detailed information on several vendors
Comprehensive details of factors that will challenge the growth of Tourette's syndrome drugs companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch